UMP Healthcare Holdings Limited Overview
UMP Healthcare is a mid-sized, founder-controlled Hong Kong private healthcare platform whose economic engine is the design and administration of outpatient medical benefit plans for corporations and insurers, backed by an owned clinical estate and a contracted affiliate network of more than 1,000 service points across Hong Kong, Macau and the Chinese Mainland. Unlike pure clinic chains, UMP earns a large share of its revenue as a managed-care intermediary and third-party administrator (TPA), then captures internal referrals into its own general practice, specialist, dental, imaging (ProCare) and laboratory facilities. The group generated HK$717.0 million of revenue in FY2026, carries no bank debt and holds HK$331.3 million of cash, yet its returns have compressed for four consecutive years as immigration medical examination demand normalised, Hong Kong consumers shifted spending to Shenzhen and imaging investments depressed margins. FY2026 produced the first net loss in the period reviewed, driven by HK$96.8 million of non-cash impairments and Foshan start-up costs.
Company's own description (FY2026 annual results announcement)
In its FY2026 announcement, UMP describes itself as operating an integrated private healthcare platform that combines self-operated core clinical assets with selected strategic partnerships to create synergies across business lines, characterising this as an asset-light model that broadens service scope and market coverage while keeping capital commitments prudent and operations flexible. Management identifies three business lines: (1) Hong Kong & Macau Corporate Healthcare Solutions; (2) Hong Kong & Macau Clinical Services; and (3) Chinese Mainland Healthcare Services. The FY2025 Chairman's Statement framed the model as a "one-stop" ecosystem of Corporate Solutions, Medical Centres and Diagnostic Imaging in which corporate clients drive volume into the group's centres and diagnostics while clinical quality enhances the value of the corporate offering.
Business model and revenue model
| Revenue model element | Mechanism | Segment | Indicative weight (FY2026) |
|---|---|---|---|
| Capitation plan contracts | Fixed per-member fees paid upfront by employers/insurers; UMP bears utilisation risk | HK & Macau Corporate | Part of 264.7 external revenue (split not disclosed) |
| Annual retainer contracts | Fixed annual fees, recognised over time | HK & Macau Corporate | Part of 264.7 (split not disclosed) |
| Fee-for-service contracts | Billed per treatment, typically due in 30–60 days | HK & Macau Corporate | Part of 264.7 (split not disclosed) |
| TPA fees (hotline, pre-approval, claims) | Administrative fees from insurers, including Mainland insurers' cross-border members | HK & Macau Corporate / Mainland | — |
| Self-paid clinical services | Cash/card payment at point of service (GP, specialist, dental, imaging, lab, IME, physio, TCM) | HK & Macau Clinical; Mainland | 412.8 (HK & Macau) + 39.5 (Mainland) |
| Government tenders and PPP programmes | Outsourced imaging out-referrals, civil service dental, nurse clinic and allied-health pilots | HK & Macau Clinical | — |
UMP's revenue model is overwhelmingly service-based; there is no material product, licensing or software revenue. It can be decomposed as follows:
Revenue recognised at a point in time was HK$588.1 million in FY2026 (FY2025: 594.3) and over time HK$128.9 million (FY2025: 132.6), which approximates the split between transactional clinical revenue and contract/retainer revenue.
Value chain position
UMP sits at three points of the outpatient value chain simultaneously: (i) payer-side administrator/plan manager (designing plans, managing networks, adjudicating pre-approvals and claims for insurers and employers); (ii) network orchestrator (contracting affiliated doctors, dentists and auxiliary providers who are paid per plan member treated, recorded as "professional services expenses" of HK$262.6 million in FY2026, or 36.6% of revenue); and (iii) direct provider (owned medical centres, six integrated medical and advanced imaging centres and one central medical laboratory at 30 June 2026). Approximately HK$151.5 million of FY2026 segment revenue was inter-segment, largely clinical services sold to the corporate solutions business, demonstrating the internal referral loop.
Customer types and end-markets
Contract customers comprise insurance companies (covering policyholders or employees of policyholders) and corporations (covering employees and dependants); the website cites more than 2,000 insurer, multinational and blue-chip clients. The group discloses customer concentration: in 1H FY2026, "Customer A" contributed HK$23.3 million and "Customer B" HK$12.3 million of corporate-segment revenue (1H FY2025: 24.5 and 18.0), together roughly 9.7% of group revenue for the half. Related companies of Chow Tai Fook Enterprises (CTFE), a substantial shareholder, are also customers (trade receivables of HK$8.8 million due from them at 30 June 2026). Self-paid patients include walk-in Hong Kong residents, emigrants and students requiring immigration medical examinations, and Mainland residents seeking Hong Kong specialist care. End-markets are Hong Kong private outpatient care, Hong Kong employee benefits/group medical insurance administration, Macau corporate healthcare, and Mainland health check-ups and outpatient care (Beijing, Shanghai, Guangzhou, Foshan).
Independent characterisation
Analytically, UMP is best understood as a managed-care TPA with a captive provider arm, not a hospital or specialty clinic operator. The corporate solutions segment is the most profitable and stable earnings source (segment margin of 16.1% in FY2026), while the Hong Kong clinical segment carries most of the fixed cost (owned centres, imaging capex, leases) and has seen its margin collapse from 13.7% in FY2022 to 2.9% in FY2026. The Mainland business is sub-scale (5.5% of external revenue) and swung to a segment loss in FY2026 because of the Foshan pilot. The group's strategic pivot is to monetise its TPA know-how cross-border (Mainland insurers' members accessing Hong Kong care; Hong Kong plan members accessing Mainland tertiary hospitals) and to relocate back-office labour to Foshan.
Strategy
Stated strategy (paraphrased themes)
- FY2025 Annual Report — four strategic pillars (Chairman's Statement): (1) Regional expansion, starting with a community healthcare centre in Guangdong and searching for partners/investments in other Mainland provinces; (2) Digital transformation (smart clinic systems, telemedicine, AI-assisted diagnostics, digital health platforms); (3) Preventive medicine and service diversification aligned with Hong Kong Government policy; (4) Talent development.
FY2025 Co-CEO joint priorities: deepening integration, investing in people, embracing innovation, expanding regionally.
1H FY2026 outlook: evolve from a traditional service operator into a holistic healthcare-ecosystem coordinator connecting patients, payers and providers; expand self-operated and affiliated centres while consolidating overlaps; deepen cross-boundary referral mechanisms.
FY2027 priorities (FY2026 announcement): (i) operational efficiency and cost control under an asset-light hybrid model; (ii) expansion of the Foshan back-office hub; (iii) technology-enabled innovation (UMP Member App, EPA penetration, eHealth integration, AI automation); (iv) network and service growth with emphasis on preventive care and Mainland commercial insurance/TPA; (v) specialist partnerships and new plan products (including concierge-style offerings); (vi) government collaboration (PPP programmes, tenders, community screening). Management also commits to aligning its roadmap with Hong Kong regulation and the strategic priorities of China's 15th national health plan.
Strategic initiatives register (last 24 months)
| Initiative | Timing | Scope | Status |
|---|---|---|---|
| Electronic Pre-Approval platform | Launched FY2025; broader rollout FY2026 | Digitises pre-approval/claims with insurers | Live; penetration being deepened |
| New Clinic Management System | Launched end-FY2025; refined FY2026 | Paperless workflows, booking, drug and inventory management | Live |
| New corporate identity | FY2025 | Rebrand at 35th anniversary | Complete |
| Mainland insurer TPA partnerships | FY2025–FY2026 | White-label TPA for Mainland insurers; cross-border members using Hong Kong network | Several partnerships signed (counterparties not named) |
| GBA back-office relocation | FY2025–FY2026 | Data processing, claims, customer service, IT moved to Foshan | Executed; hub to expand in FY2027 |
| Mainland IT team | 2,025 | Supports automation/digitalisation | Operating |
| Foshan Community Healthcare Centre pilot | Established 1H FY2026 | Primary care pilot aligned with national primary-care reform | In ramp-up; loss-making in FY2026 |
| Guangzhou IME arrangement | 2,025 | Expand immigration medicals in South China | Operating |
| UMP Member App and corporate portal upgrade | FY2026 | Member engagement and claims transparency | Launched |
| Government tenders (imaging out-referrals, civil service dental) | 1H FY2026 | Diversify revenue, raise equipment utilisation | Won |
| Nurse clinic and allied-health pilots | FY2026 | Community primary care | Operating |
| Specialist partnership with 仁德醫健集團 | FY2026 | Expand specialist capacity without in-house hiring | Signed |
| Tertiary hospital TPA cooperation (Shanghai East Hospital) | FY2026 | Mainland TPA network | Operating |
| ProCare Physiotherapy consolidation | Sep 2026 | Unified physiotherapy brand | Complete |
| AI use cases (claims document processing, workflow automation, imaging triage) | FY2026–FY2027 | Productivity | Evaluation / early deployment |
Sustainability and cost programmes
Environmental targets set in the FY2024 report: 5% intensity reduction by 2030 for GHG emissions, electricity, waste and water (Hong Kong operations); smart energy monitoring at the TST centre. Cost programmes are qualitative — workforce optimisation (employee costs -8.6% in FY2025), centre consolidation (right-of-use depreciation -13.6% in FY2025 and -8.4% in FY2026), procurement tightening and lower-rent relocations. No quantified cost-saving target has been published.
Medium-term financial targets / guidance
UMP does not publish quantitative financial guidance or medium-term targets. The most recent quantitative aspiration on record — 30 million online/offline users by 2025 (3 million in Hong Kong/Macau and 27 million in the Mainland), set in September 2020 — was effectively abandoned after the December 2021 disposal of the Mainland emerging business; the group reported roughly 1.3 million end users of corporate solutions in FY2025. Management's FY2026 outlook is described as cautiously optimistic.
Products & Services
Hong Kong & Macau Corporate Healthcare Solutions
| Offering | Description / capabilities | Target customer | Launch / latest | Pricing model |
|---|---|---|---|---|
| Corporate outpatient plans (capitation) | Tailored employee outpatient benefit plans delivered through the UMP Network (>1,000 points of service) | Employers (MNCs, blue chips, SMEs) | Core since 1979/1990 | Fixed per-member fee, paid upfront |
| Annual retainer plans | Fixed-fee access/coverage arrangements | Employers | Ongoing | Annual retainer, recognised over time |
| Fee-for-service schemes | Network access billed per treatment | Employers, insurers | Ongoing | Per-treatment billing, 30–60-day terms |
| Third-party administration (TPA) | Hotline support, pre-approval, claims processing, network management, utilisation analytics | Insurers and corporate clients | Extended to insurers from c.FY2020; expanded each year | Administrative fees (not disclosed) |
| Electronic Pre-Approval (EPA) platform | Digital pre-approval workflow linking outpatient, inpatient and claims administration | Insurers, plan members | Launched FY2025; broader adoption FY2026 | Embedded in TPA fees |
| Individual-scheme TPA (B2B2C) | Cashless, form-free outpatient treatment with network pre-approval for individual policyholders | Insurers (first client: FTLife, Oct 2022) | FY2023 | — |
| Cross-border cashless network | Access for Hong Kong plan members to designated Mainland clinics (~20 service points cited in FY2024) and tertiary hospitals for inpatient support | Insurers (first major user: AXA, Nov 2023), corporates | FY2024; expanded FY2026 | — |
| White-label TPA for Mainland insurers | TPA integrated into Mainland insurers' health products for members seeking Hong Kong consultations, second opinions or elective care | Mainland insurers | FY2025 | — |
| Modular "tailor-made" plans | Add-ons including mental health support and telehealth; pay-per-use optional services | Corporates under cost pressure, SMEs | FY2025–FY2026 | Modular pricing (not disclosed) |
| Corporate health management | Preventive screenings, vaccination programmes, occupational health, chronic-disease initiatives, wellness programmes | Corporates, insurers | Ongoing | Per programme |
| UMP Member App | Appointments, medical records, claims tracking, personalised health insights | Plan members | Launched FY2026 | Free to members |
| Corporate client portal | Upgraded self-service portal for HR/benefit administrators | Corporate clients | Upgraded FY2026 | Embedded |
| Concierge-style and value-added plan products | Under exploration | Corporates and individuals | Planned FY2027 | — |
Hong Kong & Macau Clinical Healthcare Services
| Offering | Description / key capabilities | Target customer | Launch / latest | Pricing |
|---|---|---|---|---|
| General practice / family medicine | First point of contact; network of UMP medical centres; GP revenue +1.7% in FY2026 | Self-paid patients, plan members | Since 1971/1990 | Per consultation |
| Specialist practice | More than 20 specialties: cardiology, dermatology, endocrinology/diabetes, family medicine, gastroenterology & hepatology, general surgery, internal medicine, nephrology, neurology, neurosurgery, O&G, ophthalmology, orthopaedics, ENT, paediatrics, paediatric surgery, radiology, respiratory, rheumatology, urology; specialist revenue +3.4% in FY2026 | Self-paid, insured, referred | Expanded via partnerships (e.g., 仁德醫健集團 in FY2026) | Per consultation/procedure |
| Dental services | Primary (scaling, polishing) and secondary (crowns, bridges, orthodontics, implants, whitening); FY2026 dental revenue +7.4% pre-elimination, visits +9.7% | Self-paid, plan members, civil service dental tender | Ongoing; civil service dental tender won 1H FY2026 | Per treatment |
| ProCare Medical Imaging | PET-CT, MRI, CT, ultrasound, mammography (incl. 3D), X-ray, bone densitometry; six integrated medical and advanced imaging centres; AI-assisted reads deployed; imaging revenue +4.3% in FY2026 | Self-paid, referred by specialists, insurers, government out-referrals | PET-CT Admiralty Jun 2023; TST Feb 2023; Lee Garden Two Mar 2024 | Per scan (e.g., PET-CT HK$7,600 for Hong Kong Anti-Cancer Society members) |
| Central medical laboratory | Haematology, immunology, microbiology, molecular biology, cytology, histology, urinalysis, stool, allergy and drug testing | Internal referrals, network doctors | Ongoing | Per test |
| Health check-ups / preventive medicine | Body checks and screening packages | Corporates, self-paid | Ongoing | Packages |
| Immigration Medical Examinations (IME) | Visa medicals for emigrants/students | Self-paid emigrants | Peaked FY2022–FY2023; declining since | Per examination |
| UMP+ premium centres | Preventive and lifestyle medicine; health checks, GP, specialist care adjacent to ProCare imaging; Central, Causeway Bay, Tsim Sha Tsui | Affluent self-paid, corporate VIP members | Brand launched FY2024 | Premium pricing |
| ProCare Physiotherapy | All physiotherapy centres rebranded under ProCare | Self-paid, plan members | Consolidated Sep 2026 | Per session |
| UMP Chinese Medicine Centre | TCM centre in Jordan with cross-referrals; research MoU with HKBU | Self-paid, plan members | Opened Jul 2024 | Per consultation |
| SkinCentral | Dermatology and medical aesthetics; also operated at Humansa Victoria Dockside | Self-paid | Acquired; Humansa agreement Oct 2022 | Per treatment |
| Oncology, day surgery and endoscopy | At One Chinachem Central with Pedder Healthcare | Self-paid, insured | Jul 2022 | Per procedure |
| Cardiometabolic centre | Chronic-disease specialist centre at Wing On House | Self-paid, insured | 2,021 | Per consultation |
| Nutrition, nursing, nurse clinics, allied health pilots | Community-based primary care and government pilots | Public programmes, self-paid | FY2026 | Per service / programme fees |
| Government PPP and tender services | Imaging out-referrals, civil service dental, eHealth-linked GP programmes, vaccination subsidies, cancer screening support | Hong Kong Government | Expanded FY2025–FY2026 | Tender pricing |
| Vaccination and video consultations | Vaccines; telemedicine | Self-paid, plan members | Ongoing | Per service |
Chinese Mainland Healthcare Services
| Offering | Description | Location | Launch / latest |
|---|---|---|---|
| Health check-up centres | Health assessments, including IME | Beijing, Shanghai | Beijing presence since c.2006; Shanghai Xintiandi from 2016 |
| Selected outpatient services | Family medicine and selected specialties at owned clinics | Beijing, Shanghai, GBA | Ongoing |
| Guangzhou IME cooperative arrangement | Cooperative business arrangement supporting immigration medicals in South China | Guangzhou | 2,025 |
| Foshan Community Healthcare Centre (pilot) | 25,300 sq ft, four storeys; floors 1–3 outpatient complex (15,780 sq ft) with preventive health assessment, clinical medicine, TCM, rehabilitation, dental, radiology, laboratory; floor 4 TPA office (9,515 sq ft) | Nanhai District, Foshan | Established 1H FY2026; operating through FY2026 |
| Foshan shared-services hub | Hotline, claims administration, data processing, IT support, business development | Foshan | Functions relocated during FY2026 |
| Mainland TPA network | Cooperation with tertiary hospitals including Shanghai East Hospital and international medical departments | Shanghai and others | FY2026 |
Financial Narrative
Income statement
Sources: annual results announcements FY2023, FY2024, FY2026; FY2025 Annual Report. FY2022 profit for the year includes HK$1.2 million from the discontinued GBA Healthcare operation.
Note: blank cells = not disclosed on a comparable basis. The company reported FY2022 EBITDA of HK$167.1 million under its old definition; it did not restate FY2022 to the new definition. FY2024 "adjusted EBITDA" of 78.4 is the FY2025 Annual Report's restated comparative (the FY2024 announcement itself cited core EBITDA of HK$66.8 million excluding only the HK$18.0 million profit-guarantee gain — a definitional discrepancy).
Revenue CAGR FY2022–FY2026: 1.9% per annum (HK$665.9 million to HK$717.0 million). FY2023–FY2026 CAGR: -0.5%.
Income statement commentary. Revenue growth stalled after FY2024. The FY2023 step-up (+9.2%) came from post-pandemic reopening, emigration-driven IME and imaging/specialist expansion; FY2024 (+2.9%) was supported by new imaging centres and corporate utilisation; FY2025 (-2.9%) and FY2026 (-1.4%) reflect IME normalisation and softer self-paid demand. Operating cost discipline was real but insufficient: employee costs fell 8.6% in FY2025 on workforce optimisation, and right-of-use depreciation declined from HK$71.0 million (FY2024) to HK$56.2 million (FY2026) through centre consolidation, yet professional services costs rose to 36.6% of revenue in FY2026 (35.4% in FY2025). The defining feature of FY2026 is the HK$82.0 million goodwill impairment (HK$76 million on the Hong Kong medical services CGU, HK$6 million on the Hong Kong dental CGU), HK$13.9 million impairment of an owned property and HK$0.9 million associate impairment, which together pushed "other expenses" to HK$167.5 million (23.4% of revenue). Excluding these, adjusted EBITDA still fell 20.7% to HK$75.2 million because of Foshan start-up costs and lower IME volumes. The effective tax charge of HK$8.0 million on a pre-tax loss reflects the non-deductibility of impairments (HK$16.8 million tax effect of non-deductible expenses).
Balance sheet
Note: FY2024 total assets are HK$1,106.4 million per the FY2024 announcement; the FY2025 Annual Report presents a slightly different comparative of HK$1,106.8 million (current assets restated to HK$489.5 million). The difference (HK$0.4 million) is immaterial and unexplained in the sources reviewed.
Balance sheet commentary. The balance sheet is conservatively financed: no bank borrowings or facilities in any year reviewed, a growing cash pile (HK$331.3 million, 33.4% of total assets) and net cash of HK$187.3 million even after including all lease liabilities and shareholder loans to subsidiaries. The quality of the asset base has shifted: goodwill and intangibles fell from 21.6% of total assets in FY2022 to 11.7% in FY2026 after the FY2026 write-down, materially de-risking future impairment exposure (remaining goodwill HK$76.3 million). PP&E rose sharply in FY2023 (imaging equipment purchased under August 2022 contracts) and has since been depreciated and impaired back to FY2022 levels. Equity attributable to owners fell 13.8% to HK$640.2 million in FY2026.
Cash flow
Blank cells: FY2026 cash-flow statement not yet published (annual report pending at research cut-off). Discrepancy: FY2025 capex is HK$12.3 million in the FY2025 Annual Report MD&A, HK$11.6 million in S&P data and HK$5.2 million in the FY2026 announcement's segment comparatives (which counts only PP&E additions and deposits by segment). FY2022–FY2023 dividends recognised exceed cash paid because part of the finals were settled in scrip (17.3 million shares in FY2022; 18.3 million shares in FY2023 at a deemed HK$0.78). The group has not conducted open-market buybacks for cancellation; purchases relate solely to the Share Award Scheme.
Cash flow commentary. Operating cash generation has been resilient at HK$150–190 million in FY2023–FY2025, well above reported net profit because of high non-cash D&A (HK$100–115 million per year). However, the true distributable cash flow after lease payments was thin until FY2025 (HK$14–19 million in FY2023–FY2024) because of the imaging capex cycle and HK$66–73 million annual lease outflows. FY2025's HK$77.7 million post-lease free cash flow — driven by capex collapsing to around HK$12 million — explains the 18.2% rise in cash despite an 85% payout. FY2026 cash still rose HK$28.5 million to HK$331.3 million despite the reported loss, confirming that the loss is predominantly non-cash.
Ratios
Direct costs = professional services expenses plus cost of inventories consumed. FY2026 interest coverage and ROIC are negative because of impairments; excluding the HK$96.8 million of FY2026 impairments, EBIT would have been approximately HK$33.9 million and interest coverage approximately 5.4x (analyst-calculated).
Ratio commentary. Returns have deteriorated in a straight line since FY2022: ROE fell from 10.3% to 4.2% before FY2026's loss, and ROIC on an underlying basis has settled around 5–6%, below any reasonable cost of equity for a HK$0.3 billion small-cap. Liquidity and solvency are not concerns — the current ratio of 2.11 and net cash position give ample headroom. Working capital is structurally near-neutral because the group pays affiliated providers on terms similar to or longer than its collection terms from contract customers (one-month standard credit, up to two months for major customers); receivables ageing deteriorated modestly in FY2026 (balances over three months rose to HK$9.1 million from HK$5.3 million).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (HKD Mn, before elimination)
| Segment revenue (HKD Mn, before elimination) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
HK & Macau Corporate Healthcare Solutions | 237.0 | 246.2 | 255.8 | 266.5 | 266.3 |
HK & Macau Clinical Healthcare Services | 500.4 | 562.8 | 583.1 | 558.3 | 562.0 |
Chinese Mainland Clinical Healthcare Services | 37.6 | 44.7 | 43.1 | 39.0 | 40.2 |
Inter-segment elimination | -109.1 | -126.5 | -133.5 | -136.8 | -151.5 |
Group revenue | 665.9 | 727.2 | 748.5 | 726.9 | 717.0 |
Segment external revenue (HKD Mn)
| Segment external revenue (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
HK & Macau Corporate Healthcare Solutions | 235.2 | 244.7 | 254.5 | 264.8 | 264.7 |
HK & Macau Clinical Healthcare Services | 393.1 | 437.8 | 450.9 | 423.2 | 412.8 |
Chinese Mainland Clinical Healthcare Services | 37.6 | 44.7 | 43.1 | 39.0 | 39.5 |
Contribution to group external revenue (%)
| Contribution to group external revenue (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
HK & Macau Corporate Healthcare Solutions | 35.3 | 33.7 | 34.0 | 36.4 | 36.9 |
HK & Macau Clinical Healthcare Services | 59.0 | 60.2 | 60.2 | 58.2 | 57.6 |
Chinese Mainland Clinical Healthcare Services | 5.6 | 6.1 | 5.8 | 5.4 | 5.5 |
Revenue by Segment
| Segment result (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
HK & Macau Corporate Healthcare Solutions | 35.3 | 45.0 | 39.6 | 45.0 | 42.9 |
HK & Macau Clinical Healthcare Services | 68.6 | 32.0 | 17.2 | 20.1 | 16.4 |
Chinese Mainland Clinical Healthcare Services | 1.5 | 16.8 | 13.7 | 7.6 | -7.4 |
Total segment operating results | 105.4 | 93.8 | 70.5 | 72.6 | 51.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment margin on pre-elimination revenue (%) (analyst-calculated)
| Segment margin on pre-elimination revenue (%) (analyst-calculated) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
HK & Macau Corporate Healthcare Solutions | 14.9 | 18.3 | 15.5 | 16.9 | 16.1 |
HK & Macau Clinical Healthcare Services | 13.7 | 5.7 | 3.0 | 3.6 | 2.9 |
Chinese Mainland Clinical Healthcare Services | 4.1 | 37.6 | 31.8 | 19.4 | -18.5 |
Group total | 13.6 | 11.0 | 8.0 | 8.4 | 6.0 |
YoY growth in segment revenue (%)
| YoY growth in segment revenue (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
HK & Macau Corporate Healthcare Solutions | 3.9 | 3.9 | 4.2 | -0.1 |
HK & Macau Clinical Healthcare Services | 12.5 | 3.6 | -4.3 | 0.7 |
Chinese Mainland Clinical Healthcare Services | 18.8 | -3.5 | -9.5 | 3.0 |
Segment Assets & Liabilities
| Item (HKD Mn) | Corporate FY2025 | Corporate FY2026 | HK Clinical FY2025 | HK Clinical FY2026 | Mainland FY2025 | Mainland FY2026 |
|---|---|---|---|---|---|---|
Segment assets | 245.8 | 224.8 | 287.3 | 217.6 | 34.8 | 56.3 |
Segment liabilities | 125.7 | 120.8 | 218.2 | 205.9 | 18.0 | 50.5 |
Depreciation & amortisation | 15.7 | 15.6 | 86.8 | 76.0 | 3.3 | 5.9 |
Capital expenditure | 1.6 | 1.5 | 3.1 | 10.5 | 0.4 | 13.9 |
Operating Metrics (number)
| Visits by segment (number) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
HK & Macau corporate healthcare solution visits | 849,405 | 988,091 | 1,287,532 | 1,217,311 | 1,102,512 |
HK & Macau clinical healthcare visits (self-paid) | 255,609 | 253,528 | 228,850 | 199,487 | 183,324 |
Chinese Mainland clinical visits | 28,640 | 34,558 | 35,433 | 32,216 | 35,683 |
Total visits | 1,133,654 | 1,276,177 | 1,551,815 | 1,449,014 | 1,321,519 |
Income statement (HKD Mn)
| Income statement (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (continuing) | 665.9 | 727.2 | 748.5 | 726.9 | 717.0 |
Other income and gains | 21.4 | 19.6 | 35.9 | 14.2 | 12.6 |
Professional services expenses | -238.0 | -255.4 | -270.9 | -257.0 | -262.6 |
Employee benefit expense | -164.7 | -179.8 | -197.0 | -180.0 | -184.6 |
Property rental and related expenses | -11.1 | -14.0 | -16.6 | -15.4 | -15.4 |
Cost of inventories consumed | -37.6 | -45.2 | -56.2 | -56.7 | -59.9 |
Depreciation and amortisation | -78.6 | -103.9 | -113.8 | -105.8 | -97.5 |
Other expenses (incl. impairments) | -65.8 | -74.0 | -81.6 | -77.9 | -167.5 |
Finance cost | -3.9 | -5.7 | -6.9 | -7.3 | -6.3 |
Share of JV and associate results | -1.6 | -4.3 | -0.6 | -0.5 | -0.5 |
Profit before tax (continuing) | 86.0 | 64.4 | 40.6 | 40.5 | -64.8 |
Income tax | -11.9 | -8.6 | -5.4 | -8.6 | -8.0 |
Profit for the year (incl. discontinued) | 75.2 | 55.7 | 35.2 | 31.9 | -72.7 |
Profit attributable to owners | 72.2 | 60.5 | 40.6 | 31.4 | -74.6 |
Non-controlling interests | 3.1 | -4.7 | -5.4 | 0.5 | 1.9 |
Profitability measures (HKD Mn)
| Profitability measures (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross profit, analyst-derived (revenue less professional services and inventories) | 390.3 | 426.5 | 421.4 | 413.2 | 394.5 |
EBIT, analyst-calculated (PBT + finance cost - interest income) | 88.5 | 66.9 | 42.0 | 42.6 | -62.9 |
EBITDA, all D&A added back (analyst-calculated; equals company's pre-FY2024 definition) | 167.1 | 170.8 | 155.8 | 148.4 | 34.6 |
EBITDA, company definition (excludes ROU depreciation add-back) | — | 100.9 | 84.8 | 87.0 | -21.6 |
Adjusted EBITDA, company definition (ex impairments and one-offs) | — | — | 78.4 | 94.9 | 75.2 |
Total segment operating results | 105.4 | 93.8 | 70.5 | 72.6 | 51.9 |
Pre-tax income | 86.0 | 64.4 | 40.6 | 40.5 | -64.8 |
Net income attributable | 72.2 | 60.5 | 40.6 | 31.4 | -74.6 |
Per-share data (HK cents)
| Per-share data (HK cents) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EPS basic | 9.34 | 7.65 | 5.08 | 3.98 | -9.42 |
EPS diluted | 9.33 | 7.65 | 5.08 | 3.98 | -9.42 |
Dividends per share (interim + final) | 4.50 | 4.70 | 3.30 | 3.30 | 2.80 |
Margins (%)
| Margins (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin, analyst-derived | 58.6 | 58.7 | 56.3 | 56.8 | 55.0 |
EBIT margin, analyst-calculated | 13.3 | 9.2 | 5.6 | 5.9 | -8.8 |
EBITDA margin, all D&A (analyst-calculated) | 25.1 | 23.5 | 20.8 | 20.4 | 4.8 |
EBITDA margin, company definition | — | 13.9 | 11.3 | 12.0 | -3.0 |
Adjusted EBITDA margin, company definition | — | — | 10.5 | 13.1 | 10.5 |
Net margin (profit for the year / revenue) | 11.3 | 7.7 | 4.7 | 4.4 | -10.1 |
Balance Sheet
| Balance sheet (HKD Mn, at 30 June) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 1,037.6 | 1,121.3 | 1,106.4 | 1,095.3 | 990.7 |
Property, plant and equipment | 141.5 | 205.5 | 212.9 | 177.9 | 141.5 |
Right-of-use assets | 136.0 | 107.9 | 107.2 | 96.5 | 88.2 |
Goodwill | 164.8 | 164.8 | 164.2 | 156.6 | 76.3 |
Other intangible assets | 59.9 | 48.2 | 37.9 | 37.9 | 40.1 |
Goodwill and intangibles combined | 224.6 | 213.0 | 202.0 | 194.5 | 116.3 |
Trade receivables | 81.4 | 121.1 | 131.0 | 120.7 | 125.4 |
Cash, bank balances and deposits | 238.1 | 290.5 | 256.1 | 302.8 | 331.3 |
Total current assets | 432.8 | 495.5 | 489.1 | 536.8 | 556.8 |
Total current liabilities | 194.5 | 271.1 | 270.4 | 269.1 | 264.1 |
Net current assets (working capital) | 238.3 | 224.4 | 218.7 | 267.7 | 292.7 |
Bank borrowings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Loans from non-controlling shareholders (current) | 0.0 | 48.8 | 51.9 | 53.2 | 46.4 |
Lease liabilities, current | 63.3 | 58.5 | 53.5 | 55.5 | 43.7 |
Lease liabilities, non-current | 85.1 | 64.9 | 67.2 | 52.9 | 53.8 |
Total debt incl. leases and NCI loans (analyst-calculated) | 148.3 | 172.2 | 172.6 | 161.6 | 144.0 |
Short-term debt (NCI loans + current leases) | 63.3 | 107.3 | 105.4 | 108.7 | 90.1 |
Long-term debt (non-current leases) | 85.1 | 64.9 | 67.2 | 52.9 | 53.8 |
Net debt (total debt less cash; negative = net cash) | -89.8 | -118.3 | -83.5 | -141.2 | -187.3 |
Equity attributable to owners | 698.7 | 740.5 | 725.9 | 742.6 | 640.2 |
Non-controlling interests | 38.7 | 29.2 | 18.3 | 9.2 | 12.1 |
Total equity | 737.3 | 769.7 | 744.3 | 751.8 | 652.3 |
Cash flow (HKD Mn)
| Cash flow (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (S&P data) | 110.9 | 190.0 | 148.8 | 152.0 | — |
Capital expenditure, company-reported | 84.5 | 109.3 | 57.2 | 12.3 | 25.9 |
Free cash flow (OCF less S&P capex) | 26.4 | 80.7 | 91.5 | 140.3 | — |
Lease principal payments (S&P data) | 55.0 | 66.4 | 73.0 | 62.6 | — |
Free cash flow after leases (S&P data) | -28.6 | 14.3 | 18.5 | 77.7 | — |
Dividends paid, cash (S&P data) | 22.0 | 23.1 | 34.4 | 27.6 | — |
Dividends recognised as distribution (company) | 33.2 | 37.1 | 34.4 | 27.2 | 26.6 |
Share purchases for share award scheme (S&P data) | 0.2 | 2.5 | 0.5 | 0.2 | — |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratios (analyst-calculated unless noted) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, attributable profit / closing owners' equity (%) (company-reported basis) | 10.3 | 8.2 | 5.6 | 4.2 | -11.7 |
ROA, profit for year / total assets (%) | 7.3 | 5.0 | 3.2 | 2.9 | -7.3 |
ROIC, EBIT x (1-16.5%) / (equity + debt - cash) (%) | 11.4 | 8.6 | 5.3 | 5.8 | -11.3 |
Current ratio (x) (company-reported) | 2.23 | 1.83 | 1.81 | 1.99 | 2.11 |
Debt incl. leases and NCI loans / total equity (x) | 0.20 | 0.22 | 0.23 | 0.21 | 0.22 |
Company gearing ratio, NCI loans / total equity (%) | 0.0 | 6.3 | 7.0 | 7.1 | 7.1 |
Net debt / EBITDA all D&A (x) | -0.54 | -0.69 | -0.54 | -0.95 | -5.41 |
Interest coverage, EBIT / finance cost (x) | 22.6 | 11.8 | 6.0 | 5.8 | -10.0 |
Asset turnover, revenue / total assets (x) | 0.64 | 0.65 | 0.68 | 0.66 | 0.72 |
Days sales outstanding (days) | 44.6 | 60.8 | 63.9 | 60.6 | 63.8 |
Days inventory on direct costs (days) | 11.7 | 15.1 | 16.5 | 17.0 | 17.3 |
Days payables on direct costs (days) | 51.8 | 77.8 | 84.6 | 71.7 | 80.7 |
Cash conversion cycle (days) | 4.5 | -1.9 | -4.2 | 5.9 | 0.4 |
Geographic revenue (HKD Mn)
| Geographic revenue (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong | 609.9 | 666.8 | 690.2 | 672.6 | 663.0 |
Chinese Mainland | 37.6 | 44.7 | 43.1 | 39.0 | 39.5 |
Macau | 18.3 | 15.7 | 15.2 | 15.3 | 14.5 |
Total | 665.9 | 727.2 | 748.5 | 726.9 | 717.0 |
Geographic revenue growth (%)
| Geographic revenue growth (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Hong Kong | 9.3 | 3.5 | -2.5 | -1.4 |
Chinese Mainland | 18.8 | -3.5 | -9.5 | 1.2 |
Macau | -14.1 | -3.6 | 1.0 | -5.2 |
Geographic share of revenue (%)
| Geographic share of revenue (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Hong Kong | 91.6 | 91.7 | 92.2 | 92.5 | 92.5 |
Chinese Mainland | 5.6 | 6.1 | 5.8 | 5.4 | 5.5 |
Macau | 2.7 | 2.2 | 2.0 | 2.1 | 2.0 |
Segment (HKD Mn) Overview
| Segment (HKD Mn) | Hong Kong | Chinese Mainland | Macau | Total |
|---|---|---|---|---|
Corporate Healthcare Solutions | 253.0 | 0.0 | 11.7 | 264.7 |
Clinical Healthcare Services | 409.9 | 39.5 | 2.8 | 452.3 |
Total | 663.0 | 39.5 | 14.5 | 717.0 |
Revenue by service type (HKD Mn)
| Revenue by service type (HKD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Medical services | 591.2 | 649.1 | 676.8 | 657.1 | 643.9 |
Dental services | 74.7 | 78.1 | 71.7 | 69.9 | 73.0 |
Share Price & Returns
| Reference point | Price (HKD) | Note |
|---|---|---|
IPO (27 Nov 2015) | 2.06 | Listing price |
25 Sep 2020 | 1.23 | Post-FY2020 results intraday (Gelonghui) |
Scrip dividend deemed price (FY2022 and FY2023 finals) | 0.78 | Company circulars Dec 2021 / Dec 2022 |
Jan–Mar 2025 | 0.42–0.46 | ETNet quotes |
52-week range (to Oct 2026) | 0.315–0.50 | StockAnalysis |
Early Oct 2026 | 0.39–0.405 | StockAnalysis / MarketScreener |
Performance | Return | Source |
Year-to-date 2026 (to 9 Oct 2026) | -13.8% | MarketScreener |
1-year (market cap change) | approx. -17.5% | StockAnalysis |
Since IPO | approx. -80% (excluding dividends) | Analyst-calculated vs HK$2.06 |
Valuation Multiples
| Multiple | UMP | Basis |
|---|---|---|
P/E (FY2026) | Not meaningful (loss) | EPS -9.42 cents |
P/E (FY2025) | ~10.1x | EPS 3.98 cents |
P/B | ~0.51x | Owners' equity HK$640.2 million |
EV (incl. leases, NCI loans and NCI, less cash) | ~HK$149 million | 324 + 144.0 + 12.1 - 331.3 |
EV/Sales | ~0.21x | FY2026 revenue 717.0 |
EV/Adjusted EBITDA (company definition) | ~2.0x | 75.2 |
EV/EBITDA (all D&A, ex impairments) | ~1.1x | 34.6 + 96.8 = 131.4 |
Dividend yield | ~7.0% | HK2.80 cents |
Dividend per share (HK cents)
| Dividend per share (HK cents) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim | 1.50 | 1.70 | 1.30 | 1.40 | 1.40 |
Final | 3.00 | 3.00 | 2.00 | 1.90 | 1.40 |
Total | 4.50 | 4.70 | 3.30 | 3.30 | 2.80 |
Analyst Conclusions
Management guidance
No numeric guidance. Management remains cautiously optimistic, prioritising cost control, scaling the Foshan hub, digital adoption, preventive care, specialist partnerships and government collaboration in FY2027, and characterising FY2026 impairments as non-recurring.
Consensus expectations
No reliable consensus exists (single broker; stale aggregator data). Implicitly, the market prices UMP at ~0.5x book and ~2x adjusted EBITDA, discounting continued low growth and limited capital reallocation.
Bull case
-
Earnings rebound from a cleaner base: with HK$96.8 million of FY2026 impairments non-recurring and D&A falling (HK$97.5 million vs HK$113.8 million in FY2024), even flat adjusted EBITDA of ~HK$75 million could restore net profit of roughly HK$20–30 million (analyst estimate) as Foshan losses narrow.
-
Cash-rich, deeply undervalued: net cash of HK$187.3 million represents ~58% of market cap; EV of ~HK$149 million for a business generating HK$150 million of annual operating cash flow (FY2023–FY2025) leaves substantial margin of safety, and a ~7% yield pays investors to wait.
-
Cross-border TPA optionality: Mainland insurer white-label partnerships, AXA network and tertiary-hospital cooperation position UMP to monetise GBA healthcare integration with little capital.
Bear case
-
Structural decline in Hong Kong clinical economics: segment margin of 2.9%, visits down 14.8% from peak and Shenzhen leakage suggest the owned-clinic estate may not earn its cost of capital; further impairments on the remaining HK$76.3 million goodwill or PP&E remain possible.
-
Value trap governance: founder plus strategic shareholders control ~64%; free float is thin, institutional ownership ~0.2%, and history shows cash accumulating rather than being returned via buybacks; the dividend was cut 15% in FY2026.
-
Mainland execution risk: the group exited its last Mainland expansion in 2021; the Foshan pilot already flipped the segment to a HK$7.4 million loss and could absorb further capital.
Catalysts and monitorables (next 12 months)
-
2026 Annual Report (Oct 2026): FY2026 operating cash flow, director remuneration, impairment assumptions.
-
AGM on 20 Nov 2026: repurchase mandate, board composition votes.
-
1H FY2027 interim results (expected late Feb 2027): Foshan losses, Mainland TPA revenue, adjusted EBITDA trend.
-
Any announced GBA M&A or partnership (stated exploration).
-
Hong Kong public healthcare fee reform effects on private volumes; government tender wins.
-
Corporate segment renewals and concentration (Customers A and B).
-
Further IME trends and cross-border dental leakage.
-
Insider purchases or any controlling-shareholder action (privatisation would be consistent with the valuation but is purely speculative and unannounced).
Concluding analyst verdict
UMP Healthcare is a financially conservative, cash-generative but strategically stalled Hong Kong managed-care and clinic operator. Its core asset — the corporate healthcare solutions and TPA franchise, generating roughly HK$43–45 million of segment profit at a mid-teens margin — remains intact and arguably undervalued. The problem is everything around it: the Hong Kong clinical estate has seen its margin fall from 13.7% to 2.9% in four years despite consolidation, immigration medicals are in structural retreat, and Hong Kong patients are migrating north for discretionary care. FY2026's HK$74.6 million loss is predominantly a non-cash recognition of what the share price had long implied — that the acquired Hong Kong medical and dental businesses were worth less than their carrying value.
The balance sheet is the decisive mitigant. With HK$331.3 million of cash, no bank debt and EV of only around HK$150 million, the market is ascribing almost no value to an operating business that produced around HK$150 million of operating cash flow annually in FY2023–FY2025. Downside appears limited by the cash and the dividend (≈7% yield), but upside requires either a demonstrable turnaround in Hong Kong clinical profitability, credible monetisation of the cross-border TPA strategy, or a capital-allocation event (special dividend, buyback, or corporate action by controlling shareholders). None is currently signalled. The Foshan pilot adds execution risk to a management team that previously retreated from the Mainland.
On balance, UMP screens as a deep-value, low-liquidity special situation rather than a growth or quality compounder. Key data points to verify upon publication of the 2026 Annual Report are FY2026 operating cash flow, impairment-test headroom on remaining goodwill, and director remuneration relative to shareholder returns.
Prepared from public sources available to 17 October 2026: UMP Healthcare HKEX filings (FY2023, FY2024 and FY2026 annual results announcements; FY2025 Annual Report; 1H FY2026 interim results announcement), company website and press releases, SFC notice (Apr 2017), ETNet, StockAnalysis/S&P Global Market Intelligence, MarketScreener, Yahoo Finance, Simply Wall St, TipRanks, ETNet/AASTOCKS/TVB/Tencent news coverage, and peer company filings (Human Health, Town Health, EC Healthcare). Figures marked analyst-calculated are the author's derivations; no figures were estimated where disclosure was absent.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / background (as disclosed) | Committees |
|---|---|---|---|
Dr SUN Yiu Kwong (孫耀江) | Chairman, Executive Director | Founder; opened first clinic 1971, founded UMP 1990; Chairman and CEO until retiring as CEO on 1 Jan 2023; controlling shareholder | Chairman, Nomination Committee |
Dr SUN Man Kin, Michael (孫文堅) | Vice Chairman and Co-CEO, Executive Director | Co-CEO since 1 Jan 2023; leads clinical excellence, diagnostics and technology | — |
Ms KWOK Cheuk Kwan, Jacquen (郭卓君) | Co-CEO, Executive Director | With UMP for more than three decades; leads corporate solutions/managed care, strategy, M&A exploration; authorised representative | Nomination Committee (from 13 Jun 2025) |
Mr TSANG On Yip, Patrick, BBS (曾安業) | Executive Director | Senior executive of Chow Tai Fook Enterprises (described as CTFE CEO in the FY2024 announcement and as a CTFE director in 2026 filings) | Remuneration Committee |
Dr LEE Pak Cheung, Patrick (李柏祥) | Executive Director | — | — |
Ms CHENG Chi Man, Sonia (鄭志雯) | Non-executive Director | — | — |
Mr LEE Luen Wai, John, BBS JP (李聯偉) | Independent Non-executive Director | Long-serving INED | Chairman, Audit Committee; Remuneration and Nomination Committees |
Mr YEUNG Tak Bun, BBS JP (楊德斌) | Independent Non-executive Director | Joined board c.FY2024 (replacing Mr Yeung Wing Sun, Mike) | Audit Committee; Nomination Committee (from 13 Jun 2025) |
Mrs CHAN KUNG Wai Ying, Amy (陳龔偉瑩) | Independent Non-executive Director | Replaced Dr Li Kwok Tung, Donald, GBS JP (former Remuneration Committee chair) between Oct 2025 and Feb 2026 | Audit Committee |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Jan 2023 | Dr Sun Yiu Kwong retires as CEO; Dr Michael Sun and Ms Jacquen Kwok become Co-CEOs | Succession; separation of Chair/CEO |
21 Sep 2023 | Dr Lee Kar Chung, Felix re-designated from Executive to Non-executive Director | CTFE nominee |
FY2024 | INEDs Mr Yeung Wing Sun, Mike and Mr Chau Chit, Jeremy leave; Mr Yeung Tak Bun joins | Board refresh |
13 Jun 2025 | Ms Kwok and Mr Yeung Tak Bun appointed to Nomination Committee | Gender diversity on committee |
| — | Ms Cheng Chi Man, Sonia replaces Dr Felix Lee as NED; Mrs Chan Kung Wai Ying, Amy replaces Dr Donald Li as INED; Tong Mo Ting replaces Cheung Chi Wah, Patrick as company secretary | Board and secretarial refresh |
Major Shareholders
| Holder | Shares | % of issued | Date of record | Source |
|---|---|---|---|---|
Dr Sun Yiu Kwong and associates | 300,226,989 | 37.02 | 30 Jun 2025 | ETNet (company disclosures) |
Chow Tai Fook (Holding) Limited (via CTFE / Healthcare Ventures Holdings) | 123,764,027 | 15.26 | 30 Jun 2025 | ETNet |
China Resources Medical Holdings Company Limited (1515.HK) | 91,803,000 | 11.32 | 4 Feb 2026 | ETNet |
Institutional investors | ~1.5 million | ~0.19 | 2025 | Simply Wall St |
Public / other | balance | ~36 | — | Derived |
Competitive Landscape
Key Competitors
| Competitor | Listing | Overlap with UMP | Latest revenue (HKD Mn) and period | Relative positioning |
|---|---|---|---|---|
EC Healthcare (醫思健康) | 2138.HK | Hong Kong non-hospital medical services, imaging, specialists, dental, check-ups | 3770.2 (FY to 31 Mar 2026, -8.9%); net loss 412.9 | Largest non-hospital group; consumer/aesthetics-led; heavier losses |
Town Health International Medical Group (康健國際) | 3886.HK | Hong Kong GP/specialist network, corporate healthcare schemes, Mainland healthcare | 1785.6 (FY Dec 2025, -2.6%) | Larger, diversified (incl. property); direct rival in corporate schemes |
Human Health Holdings (盈健醫療) | 1419.HK | Hong Kong GP, specialist and dental networks; corporate/insurance contracts; also a partner of UMP | 644.4 (FY Jun 2025, +9.1%); 342.4 (1H FY2026, +8.4%) | Similar size; growing faster, especially dental |
Quality HealthCare Medical Services | Private | Corporate healthcare schemes, clinics, TPA | — | Long-established direct rival in managed outpatient care |
Bupa (Asia) / Bupa Hong Kong | Private (insurer) | Group medical insurance with own network administration | — | Payer-integrated competitor and potential client |
Private hospitals (e.g., Hong Kong Sanatorium & Hospital, Gleneagles Hong Kong, CUHK Medical Centre) | Private / IHH (Gleneagles) | Imaging, check-ups, specialist outpatient | — | Premium imaging/check-up competitors |
Specialist imaging and lab operators (e.g., Pedder Healthcare-affiliated centres, standalone imaging groups) | Mostly private | Imaging, laboratory | — | Fragmented; price competition cited by UMP |
Shenzhen private dental and medical providers | Mainland | Cross-border leakage of Hong Kong self-paid dental and elective demand | Not applicable | Structural substitute cited by UMP since FY2024 |
iKang Healthcare Group | Private (formerly NASDAQ) | Mainland health check-ups | — | Mainland check-up leader; UMP is sub-scale |
Meinian Onehealth Healthcare | 002044.SZ | Mainland health check-ups | — | Mainland check-up leader |
United Family Healthcare (New Frontier/NewMed) | Private | Premium international outpatient in Beijing/Shanghai/GBA | — | Competes for expatriate/insured patients in Mainland |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | UMP (FY Jun 2026) | Human Health (FY Jun 2025) | Town Health (FY Dec 2025) | EC Healthcare (FY Mar 2026) |
|---|---|---|---|---|
Revenue (HKD Mn) | 717.0 | 644.4 | 1,785.6 | 3,770.2 |
Revenue growth (%) | -1.4 | 9.1 | -2.6 | -8.9 |
Adjusted EBITDA margin (%) | 10.5 | — | — | 7.4 |
Net result (HKD Mn) | -72.7 | — | — | -412.9 |



